These Analysts Revise Their Forecasts On Argenx After Q4 Earnings

Core Insights - Argenx SE reported strong fourth-quarter results, with earnings of $8.02 per share, exceeding the consensus estimate of $6.02, and sales increased from $761.2 million to $1.32 billion, surpassing the consensus estimate of $1.29 billion [1] - The company announced positive topline results from the Phase 3 ADAPT OCULUS study for VYVGART in adults with ocular myasthenia gravis [1] Group 1 - CEO Tim Van Hauwermeiren highlighted the achievement of reaching 19,000 patients globally with VYVGART and the successful launch of the pre-filled syringe, which expanded the company's impact across generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [2] - The company made substantial progress in its development programs, advancing its pipeline towards key milestones [2] - Following the earnings announcement, analysts adjusted their price targets for Argenx shares, which closed at $771.53 [2]